Sophie Dupuis-Girod

Dr. Sophie Dupuis-Girod

orcid

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 April 2002 in New England Journal of Medicine
Verified
Journal Article
Open access
PDF file
SHSalima Hacein-Bey-Abina
Salima Hacein-Bey-Abina
FDFrançoise Le Deist
Françoise Le Deist
FCFrédérique Carlier
Frédérique Carlier
CBCécile Bouneaud
Cécile Bouneaud
CHChristophe Hue
Christophe Hue
MCMarina Cavazzana
Marina Cavazzana
X-linked severe combined immunodeficiency due to a mutation in the gene encoding the common γ (γc) chain is a lethal condition that can be cured by allogeneic stem-cell transplantation. We investigated whether infusion of autologous hematopoietic stem cells that had been transduced in vitro with the γc gene can restore the immune system in patients with severe combined immunodeficiency.

1 March 2001 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
RDRainer Döffinger
Rainer Döffinger
ASAsma Smahi
Asma Smahi
CBChristine Bessia
Christine Bessia
FGFrédéric Geissmann
Frédéric Geissmann
JFJacqueline Feinberg
Jacqueline Feinberg
JCJean-Laurent Casanova
Jean-Laurent Casanova

15 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
MFMd Marie E. Faughnan
Md Marie E. Faughnan
JMJohannes J. Mager
Johannes J. Mager
SHSteven W. Hetts
Steven W. Hetts
VPValerie A. Palda
Valerie A. Palda
KLKelly Lang-Robertson
Kelly Lang-Robertson
RZRoberto Zarrabeitia
Roberto Zarrabeitia
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease affecting multiple organ systems. The Second International HHT Guidelines provide evidence-informed consensus guidelines... Description: Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant disease with an estimated prevalence of 1 in 5000 that is characterized by the presence of vascular malformations (...

4 February 2010 in Nature
Verified
Journal Article
Open access
PDF file
RWRobin Walters
Robin Walters
SJS. Jacquemont
S. Jacquemont
AVA. Valsesia
A. Valsesia
ASA. J. de Smith
A. J. de Smith
DMD. Martinet
D. Martinet
JBJ. S. Beckmann
J. S. Beckmann
Obesity is a highly heritable disorder but the genetic associations reported to date account for only a small percentage of the inherited variation in body mass index. Two groups report deletions on chromosome16p11.2 that may explain part of the 'missing heritability' in terms of 'high-penetrance' mutations that are rare but when present are very often associated with severe obesity. This is in contrast to more common gene defects that are less closely associated with clinical symptoms. Bochukova et al. identified rare recurrent copy number variants in 300 patients with severe early-onset obesity, caused by deletions involving several genes including SH2B1, known to be involved in leptin and insulin signalling. Many of the patients also suffered neurodevelopmental disorders. Walters et al. identified deletions of at least 593 kilobases on chromosome 16p11.2 in 31 patients with a previously unrecognized type of extreme obesity. The strategy they used to identify the lesion — using small well-phenotyped cohorts of extreme phenotypes with targeted follow-up in genome-wide association studies and population cohorts — shows promise as a means of identifying 'missing heritability' in complex metabolic diseases more generally. Recently, numerous single nucleotide polymorphisms have been identified as being associated with obesity, but these loci together account for only a small fraction of the known heritable component. Here, an association is reported between rare deletions of at least 593 kilobases at 16p11.2 and a highly penetrant form of obesity. The strategy used of combining study of extreme phenotypes with targeted follow-up is promising for identifying missing heritability in obesity. Obesity has become a major worldwide challenge to public health, owing to an interaction between the Western ‘obesogenic’ environment and a strong genetic contribution1. Recent extensive genome-wide association studies (GWASs) have identified numerous single nucleotide polymorphisms associated with obesity, but these loci together account for only a small fraction of the known heritable component1. Thus, the ‘common disease, common variant’ hypothesis is increasingly coming under challenge2. Here we report a highly penetrant form of obesity, initially observed in 31 subjects who were heterozygous for deletions of at least 593 kilobases at 16p11.2 and whose ascertainment included cognitive deficits. Nineteen similar deletions were identified from GWAS data in 16,053 individuals from eight European cohorts. These deletions were absent from healthy non-obese controls and accounted for 0.7% of our morbid obesity cases (body mass index (BMI) ≥ 40 kg m-2 or BMI standard deviation score ≥ 4; P = 6.4 × 10-8, odds ratio 43.0), demonstrating the potential importance in common disease of rare variants with strong effects. This highlights a promising strategy for identifying missing heritability in obesity and other complex traits: cohorts with extreme phenotypes are likely to be enriched for rare variants, thereby improving power for their discovery. Subsequent analysis of the loci so identified may well reveal additional rare variants that further contribute to the missing heritability, as recently reported for SIM1 (ref. 3). The most productive approach may therefore be to combine the ‘power of the extreme’4 in small, well-phenotyped cohorts, with targeted follow-up in case-control and population cohorts.

25 April 2008 in Circulation Research
Verified
Journal Article
Closed access
PDF file
LDLaurent David
Laurent David
CMChristine Mallet
Christine Mallet
MKMichelle Keramidas
Michelle Keramidas
NLNoël Lamandé
Noël Lamandé
JGJean-Marie Gasc
Jean-Marie Gasc
SBSabine Bailly
Sabine Bailly
Angiogenesis is a complex process, requiring a finely tuned balance between numerous stimulatory and inhibitory signals. ALK1 (activin receptor like-kinase 1) is an endothelial-specific type 1 receptor of the transforming growth factor-β receptor family. Heterozygotes with mutations in the ALK1 gene develop hereditary hemorrhagic telangiectasia type 2 (HHT2). Recently, we reported that bone morphogenetic protein (BMP)9 and BMP10 are specific ligands for ALK1 that potently inhibit microvascular endothelial cell migration and growth. These data lead us to suggest that these factors may play a role in the control of vascular quiescence. To test this hypothesis, we checked their presence in human serum. We found that human serum induced Smad1/5 phosphorylation. To identify the active factor, we tested neutralizing antibodies against BMP members and found that only the anti-BMP9 inhibited serum-induced Smad1/5 phosphorylation. The concentration of circulating BMP9 was found to vary between 2 and 12 ng/mL in sera and plasma from healthy humans, a value well above its EC 50 (50 pg/mL). These data indicated that BMP9 is circulating at a biologically active concentration. We then tested the effects of BMP9 in 2 in vivo angiogenic assays. We found that BMP9 strongly inhibited sprouting angiogenesis in the mouse sponge angiogenesis assay and that BMP9 could inhibit blood circulation in the chicken chorioallantoic membrane assay. Taken together, our results demonstrate that BMP9, circulating under a biologically active form, is a potent antiangiogenic factor that is likely to play a physiological role in the control of adult blood vessel quiescence.

7 March 2012 in JAMA
Verified
Journal Article
Open access
PDF file
SDSophie Dupuis-Girod
Sophie Dupuis-Girod
IGIsabelle Ginon
Isabelle Ginon
JSJean-Christophe Saurin
Jean-Christophe Saurin
DMDenis Marion
Denis Marion
EGElsa Guillot
Elsa Guillot
FFFrédéric Faure
Frédéric Faure
Hereditary hemorrhagic telangiectasia (HHT) (Online Mendelian Inheritance in Man [OMIM] #187300) is a dominantly inherited genetic vascular disorder characterized by recurrent epistaxis; cutaneous telangiectasia; and visceral arteriovenous malformations (AVMs) that affect many organs, including the lungs, gastrointestinal tract, liver, and brain. Diagnosis is based on the Curaçao criteria and is considered definite if at least 3 of 4 criteria are fulfilled.1 The criteria are spontaneous and recurrent epistaxis, telangiectasia, family history, and visceral lesions.